Centro Hospitalar Universitario Sao Joao E.P.E.

The gastroenterology unit is evaluating new oral therapies to maintain remission in patients with Crohn's disease.

• Upadacitinib as maintenance therapy
• Long‑term safety monitoring
• Patient‑reported outcomes
• Dose optimization strategies

At Centro Hospitalar Universitario Sao Joao E.P.E. more than 80 investigators contribute to a portfolio of 10 active studies.

A precision‑medicine study targets motor decline in individuals with Parkinson’s disease carrying a GBA1 mutation.

• Genotype‑guided therapy
• Motor function scales
• Safety and tolerability assessments
• Impact on daily living

The trial aims to improve quality of life for patients while advancing personalized treatment options.

A comparative trial examines whether asundexian can safely reduce stroke risk in patients with atrial fibrillation.

• Efficacy in preventing stroke
• Major bleeding outcomes
• Benefit‑risk balance
• Patient adherence

Findings will inform anticoagulation strategies for individuals at high risk of thrombo‑embolic events.

Researchers assess continued viral suppression after switching to a simplified DTG/3TC regimen in treatment‑experienced adults living with HIV.

• Virologic control
• Safety profile
• Treatment convenience
• Long‑term outcomes

The study supports therapeutic options that reduce pill burden for aging patients.

A gene‑therapy approach is being tested for safety and copper regulation in patients with Wilson disease. Parallel research evaluates long‑term prophylaxis with a novel agent in individuals with haemophilia A.

• Gene delivery vectors
• Copper excretion monitoring
• Inhibitor management strategies
• Pediatric safety data

Collaboration across several European countries enhances the robustness of these rare‑disease investigations.